Viibryd (Vilazodone): Uses, Side Effects, Food Rules, and Stopping Safely

Viibryd (vilazodone) is an antidepressant for adults with major depression. Two practical details matter from the first dose: take it with food, and plan any stop with your prescriber. Here is what the FDA label and the studies actually show about benefits, anxiety, side effects, sexual effects, weight, and interactions.

What to know

• Viibryd is FDA-approved only for major depressive disorder in adults. It is not approved for children or teens, and two pediatric depression trials did not show benefit.[1,24,25]
• Take it with food. Taken without food, blood levels can drop by about half, which may reduce effectiveness.[1]
• The usual start is gradual: 10 mg once daily for 7 days, then 20 mg, with an increase to 40 mg allowed after at least another 7 days. The target dose is 20 to 40 mg.[1]
• Stomach side effects are the most common. In the label’s pooled trials, diarrhea affected 26% to 29% of people on vilazodone versus 10% on placebo, and nausea 22% to 24% versus 7%.[1]
• It is not proven to be free of sexual side effects. In pooled placebo-controlled studies, 8.0% on vilazodone reported a sexual-function side effect versus 0.9% on placebo.[19]
• Stop gradually. The label describes a taper, for example 40 mg to 20 mg for 4 days, then 10 mg for 3 days, to reduce withdrawal symptoms.[1]

Zoom

Viibryd in brief

Viibryd is the brand name for vilazodone, a prescription antidepressant approved in the United States for major depressive disorder in adults. It changes serotonin signaling in two ways, but that does not mean it works twice as well or faster than other medicines. It may help some people who have depression with anxiety. Separate anxiety disorders require a more careful discussion because those uses are not FDA approved. Two practical details matter from the start: take it with food, and discuss stopping it with your prescriber rather than stopping suddenly. This guide explains the benefits, risks, treatment timeline, and evidence behind common claims, so you and your family can take part in decisions about care.[1,2,8,9,10,11]

At a glance

These points summarize the prescribing information and clinical studies; they do not predict an individual response.[1,6,7,19,20]

What is Viibryd (vilazodone) used for?

Major depressive disorder can affect far more than mood. It can change sleep, appetite, concentration, energy, and the ability to enjoy life. Some people feel slowed down or empty. Others feel irritable, worried, or overwhelmed. A diagnosis depends on the pattern, duration, and impact of symptoms, not simply having a hard week. Treatment may involve medication, psychotherapy, or both.[4]

Viibryd is one option within that treatment plan. Its US approval is for adults with major depressive disorder. It is not approved for children or teens. It is also not an antipsychotic, a stimulant, a sleeping pill, or a mood stabilizer. Having more than one pharmacologic action does not give it a broad set of approved uses.[1]

Generic vilazodone is available. FDA-approved generics must meet standards for the active ingredient, strength, dosage form, quality, and how the medicine becomes available in the body. The tablet’s appearance and inactive ingredients may differ. A change in color does not by itself mean the medicine is weaker. Ask the pharmacist if the tablet looks unfamiliar or symptoms change after a refill. Pharmacy stock, insurance rules, and your out-of-pocket cost still vary.[3,33]

How Viibryd works in the brain

Serotonin is a chemical messenger used by nerve cells. After a cell releases serotonin, a transporter helps move some of it back into the cell. Vilazodone blocks this transporter. That action is called serotonin reuptake inhibition, the main action of SSRI antidepressants.[1]

Vilazodone also acts at a serotonin receptor called 5-HT1A. A receptor is a site where a chemical signal can change what a cell does. Vilazodone is a partial agonist there, meaning it can activate the receptor but does not produce the same maximum effect as a full agonist in a given experimental system. The overall effect depends on the receptor’s location and surrounding signals.[1]

Think of the transporter as part of a message-recycling system and the receptor as a message receiver. Vilazodone affects both. That is only a teaching comparison: brain signaling is a network, and changing one part does not tell us exactly how a person will feel.

Researchers can describe these drug actions more confidently than they can explain the full path from taking the medicine to feeling better. A 2025 structural study added detail about how vilazodone binds to the serotonin transporter. It studied molecular behavior, not whether patients recover faster. It does not establish a new use or a clinical advantage.[35]

Depression is not established to be a simple shortage of serotonin. Genes, health, life experiences, stress, and other biological processes can all matter. A medicine helping does not prove that a person had a particular chemical deficit.[4]

Vilazodone usually reaches peak blood levels several hours after a dose, and its half-life is about 25 hours. Half-life means the time needed for the amount in the body to fall by about half under the conditions studied. It does not mean the antidepressant effect starts or ends at that time.[1]

Why Viibryd must be taken with food

Take vilazodone with food. This affects how much medicine reaches the bloodstream, not just whether your stomach feels comfortable. Taking it while fasting can substantially reduce drug exposure and may reduce effectiveness. A consistent dose paired with a regular meal makes this instruction easier to follow.[1,2]

The US prescribing information does not set a universal minimum number of calories for each dose. Do not borrow a calorie rule from another psychiatric medicine. If you rarely eat breakfast, ask whether another regular meal would fit your schedule. If nausea, an eating disorder, surgery, or another health problem makes eating difficult, bring that up before changing the way you take it.

A useful appointment question is, “Could the way I am taking this explain why it seems inconsistent?” Include missed meals and missed doses in that discussion. This is information your clinician can use, not a test of whether you have been a good patient.

Morning versus evening dosing can be discussed according to sleep and side effects. The main goals are a consistent daily schedule and food with the dose. Do not change the dose or take an extra tablet to make up for having taken one without food.[1,2]

How well Viibryd works for depression

Randomized trials support vilazodone’s ability to reduce adult depression symptoms more than placebo over about eight to ten weeks. Placebo is an inactive treatment used as a comparison. These studies show an average benefit across a group. They cannot tell you in advance whether the medicine will fit your symptoms and priorities.[5,6,7]

In one eight-week study that enrolled 481 adults, about 44% of the vilazodone group met the study’s definition of response, compared with 30% of the placebo group. Response meant a substantial reduction in symptoms, not necessarily full recovery. Remission rates in that study were numerically higher with vilazodone but did not reach statistical significance.[6]

These distinctions matter. Symptom improvement means something has become easier. Response usually refers to a large drop on a rating scale. Remission means symptoms have fallen to a low level according to the study’s definition. Functional recovery includes getting back to daily responsibilities, relationships, and activities. Those changes may not happen at the same pace.

A larger ten-week study supported both 20 mg and 40 mg daily. It also included citalopram, another antidepressant. However, the study was not designed with enough statistical power to establish which active medicine was superior. Including two drugs in the same study does not automatically justify saying one is better.[7]

Many trials excluded people with certain complex conditions, high suicide risk, or several previous unsuccessful treatments. Several major studies were funded by the manufacturer or involved company-employed authors. That does not erase their findings, but it makes independent replication, negative findings, and real-world follow-up important.[5,6,7,18]

How long Viibryd takes to work

Some changes may appear early, but useful improvement usually needs several weeks. General antidepressant guidance describes a typical time frame of about four to eight weeks. Sleep or concentration may improve before mood. This is general guidance, not a vilazodone-specific deadline or a reason to wait through dangerous symptoms.[4]

One early vilazodone trial found a statistical difference from placebo at the first week measured. That finding does not mean most patients feel well within a week. It also does not prove a faster onset than another antidepressant, because the study did not make that comparison.[5]

Before starting, choose a few signs of progress that matter to you. Examples might include getting out of bed for work, spending less of the evening worrying, or having enough interest to see a friend. Track them briefly once or twice a week. A rating scale can help, but your daily life belongs in the assessment too.

Tell the clinician if there is little benefit, partial benefit, or benefit paired with difficult side effects. The next step may involve reviewing the diagnosis, food intake, missed doses, other medicines, therapy, or the treatment plan. A difficult trial is useful information. It is not proof that you cannot get better.

Viibryd for anxiety and other possible uses

Depression with anxiety

Anxiety is common during depression. An analysis of two depression trials found improvement in several anxiety measures among participants with prominent anxiety symptoms. However, this was a post hoc analysis: researchers examined a question using data from studies already completed. It supports a possible benefit for anxious depression, but it is weaker evidence than a trial designed specifically for that question.[8]

Treating depression in someone who also feels anxious is different from proving treatment of a separate anxiety disorder. If panic attacks, compulsions, trauma symptoms, or social fear are the main problem, the diagnosis and evidence should guide the choice.

Generalized anxiety disorder

Three short-term randomized trials found some benefit for generalized anxiety disorder, which involves persistent, excessive worry. In a fixed-dose trial, 40 mg separated from placebo on the main anxiety score; 20 mg did not. Two flexible-dose trials also favored vilazodone on anxiety scores, but improvement in daily functioning was less consistent across studies. The average advantage on the anxiety scale was modest.[9,10,11]

Vilazodone remains an off-label choice for this disorder in the United States. Off-label means the use is outside the FDA-approved labeling. It does not automatically mean the treatment is inappropriate. It does mean the reason for choosing it, alternatives, and the uncertainty deserve a clear discussion.[1,9,10,11]

Social anxiety and separation anxiety

A small social anxiety trial randomized 44 adults and reported an encouraging result. Its small size and use of a one-sided statistical test limit confidence. A separate 24-person pilot study of adult separation anxiety had mixed findings: some measures improved, but response rates at week 12 were not significantly different. These studies are leads for further research, not strong reasons to market vilazodone as a proven treatment for either condition.[12,15]

PTSD and other proposed uses

A 59-person trial in PTSD with depression found no significant advantage over placebo on its main or secondary outcomes. Another PTSD study is registered, but the record checked for this review listed it as not yet recruiting, with no results posted. A planned trial is not evidence of benefit.[13,14]

A cannabis-dependence pilot trial also did not show a benefit over placebo for reducing cannabis use. Research into steroid-related memory changes is preliminary and does not establish a treatment for memory loss. Adequate direct evidence was not identified here to recommend vilazodone specifically for OCD, panic disorder, ADHD, insomnia, bipolar depression, or chronic pain. Medicines in related classes may have evidence for some of those conditions; their evidence cannot simply be transferred to vilazodone.[16,36]

Starting Viibryd: dosing and everyday problems

The following describes US labeling, not a schedule to follow without a prescription. The usual labeled start is 10 mg once daily with food for seven days, then 20 mg daily. A clinician may increase it to 40 mg after at least another seven days. The usual target range is 20 to 40 mg daily. Slower changes or a different plan may be appropriate for an individual.[1]

Starting at a lower dose gives the clinician a way to assess tolerability. More milligrams do not automatically mean a better result. Interactions can also change the appropriate dose. Tell the prescriber about all prescription medicines, nonprescription products, and supplements before treatment starts.

If you miss a dose, take it when you remember unless it is nearly time for the next one. In that case, skip the missed dose. Do not take two doses together. Ask the pharmacist how to apply this instruction if timing is unclear.[2]

If you vomit after taking it, do not automatically take another tablet. The labeling states that a replacement dose is not needed when vomiting occurs within seven hours of ingestion. Persistent vomiting, inability to keep fluids down, or signs of dehydration need medical advice.[1]

Ask the pharmacist before splitting or crushing your particular tablet. Do not assume that a brand tablet and every generic product have the same tablet design. Store it as directed, away from excess moisture and out of children’s reach. Plan refills before the bottle is empty, especially before travel or an insurance change.[2,33]

Common Viibryd side effects

Stomach and bowel effects are prominent with vilazodone. Some people also have sleep changes or dizziness. The table below shows selected events reported in pooled adult depression trials lasting eight to ten weeks. The percentages describe study groups, not your personal risk.[1]

The pooled groups included 967 placebo-treated adults, 288 taking 20 mg, and 978 taking 40 mg. Different group sizes and study designs mean small numerical differences between doses should not be overinterpreted.[1]

Gastrointestinal symptoms often appeared early in trials, and many were mild or moderate. Some settled as treatment continued. That is a reason to discuss tolerable early symptoms, not an instruction to endure ongoing diarrhea or repeated vomiting. Contact the clinician if symptoms interfere with eating, drinking, working, or taking the medicine.[7,18]

For mild nausea, taking the prescribed dose with a regular meal may make the routine easier. Ask before adding an anti-nausea, sleep, or diarrhea medicine. Bring a short account: when the symptom began, when you take the tablet, what you eat with it, and how much it affects you. Specific information helps the clinician decide whether to wait, change timing, change the dose, or choose another treatment.

If you feel sleepy or dizzy, avoid driving or other hazardous tasks until you know how the medicine affects you. New severe restlessness deserves prompt attention. It is especially important to report agitation together with very little need for sleep, racing thoughts, impulsive behavior, or worsening suicidal thoughts.[1,2]

Viibryd sexual side effects and emotional changes

Vilazodone can cause sexual problems. These may involve desire, arousal, erections, ejaculation, or orgasm. Depression itself can affect sexual function, so the timing and pattern matter. Discussing how things were before treatment helps distinguish illness-related problems from possible medication effects.[1,19]

Some studies found little difference between average sexual-function questionnaire scores for vilazodone and placebo. Yet a pooled analysis reported sexual adverse events in 8.0% of vilazodone-treated participants versus 0.9% on placebo. These are different ways of measuring a problem. An average score can improve as depression lifts while some individuals develop new difficulties.[19]

A study in healthy adults compared vilazodone with paroxetine. Its main analysis did not establish a significant difference among the treatments, including between paroxetine and placebo. Later analyses excluding some participants who had not taken the medicine consistently suggested an advantage for 20 mg vilazodone over paroxetine. Those later findings do not support a broad promise that vilazodone causes fewer sexual effects than all SSRIs.[20]

You do not need to wait until a sexual problem becomes severe to mention it. Tell the clinician whether the issue is desire, physical response, orgasm, pain, or a combination. Also say whether improvement in mood has changed intimacy in other ways. Do not skip doses before sex or stop suddenly to test the cause.

If you feel emotionally flat, describe that directly. Feeling less overwhelmed is different from losing interest or feeling detached from people you care about. Residual depression, poor sleep, other health problems, and treatment effects may all need consideration. The evidence reviewed does not establish vilazodone as reliably free of emotional blunting. Persistent sexual or emotional symptoms after a medication change warrant evaluation; their cause should not be assumed from timing alone.

Viibryd and weight, appetite, and sleep

Short trials generally found small average weight changes. That does not establish that weight never changes. In a year-long uncontrolled study, people who remained to week 52 had a mean gain of about 1.7 kg, roughly 3.7 pounds. Because there was no placebo group and not everyone stayed in the study, this cannot tell us how much change was caused by the drug.[7,18]

The practical message is to notice patterns without making weight the only measure of treatment success. Appetite may change as depression changes. Report a sustained change that concerns you, along with changes in eating, activity, sleep, or other medicines. Avoid assuming a medicine is either completely weight neutral or certain to cause weight gain.

Vilazodone can interfere with sleep, and some people feel sleepy instead. Track the connection between dose timing, meals, sleep quality, and daytime function. It is not an established insomnia treatment. A sleep problem may call for a separate assessment rather than simply adding another medicine.[1,2]

Serious risks and when to seek help

All antidepressants require monitoring for worsening symptoms and suicidal thoughts, particularly early in treatment and after dose changes. The boxed warning highlights increased risk in children, adolescents, and young adults. In pooled short-term antidepressant trials, ages 18 to 24 had about five additional cases of suicidal thoughts or behaviors per 1,000 treated compared with placebo. That is class-wide evidence, not a vilazodone-specific estimate and not an estimate of suicide deaths. Depression itself also carries risk.[1]

In the United States, call or text 988 for suicidal thoughts or emotional crisis. Call 911 for immediate danger or a life-threatening medical emergency. Do not leave an immediate safety concern for the next routine appointment.[4]

Serotonin syndrome is a potentially dangerous reaction involving excessive serotonin activity. It can occur with vilazodone alone, although combinations with other serotonergic medicines increase risk. A single mild symptom does not establish the diagnosis. A concerning cluster needs urgent care.[1,2]

Other precautions include bleeding, low blood sodium, seizures, and a sudden rise in eye pressure in people with untreated narrow drainage angles. Tell the prescriber about a seizure disorder, unusual bleeding, glaucoma history, or prior low sodium. Older adults and people taking diuretics may need extra attention to sodium-related symptoms.[1,2]

Screening for bipolar disorder matters because antidepressants may trigger mania or hypomania in susceptible people. Report episodes of unusually high energy, little need for sleep, racing thoughts, or risky behavior, as well as family history. Feeling abruptly energized while sleeping very little should not automatically be called recovery.[1]

For a possible overdose or a child’s accidental ingestion, call Poison Help at 1-800-222-1222 promptly. If the person collapses, has a seizure, cannot breathe normally, or cannot be awakened, call 911.[32]

Viibryd drug interactions

Some combinations should be avoided; others can be used with a specific plan. Bring a complete list to the pharmacist, including vitamins, supplements, pain medicines, cold remedies, alcohol, cannabis, and CBD. A product sold without a prescription can still matter.

The table is not an exhaustive interaction list.[1,26]

CYP3A4 is an enzyme system involved in breaking down vilazodone. In healthy-volunteer studies, ketoconazole increased exposure, while carbamazepine reduced it. This helps explain why the usual dose cannot be judged separately from the rest of your medication list. The same concern applies when an interacting drug is discontinued.[26]

The Medication Guide advises avoiding alcohol. Laboratory findings that alcohol did not change absorption do not establish that the combination is safe. Ask about grapefruit products. Evidence for specific cannabis or CBD combinations is incomplete, so do not assume a safe dose or spacing interval. Have cold and cough products checked by ingredient rather than brand name.[1,2]

See also drug interactions to know with antidepressants, alcohol, CBD, and more.

Pregnancy, breastfeeding, and other special situations

If you are pregnant or planning pregnancy, ask for a review before changing treatment. Human pregnancy data specific to vilazodone remain limited. That uncertainty does not prove either safety or harm. The risks of untreated depression, your previous response, other options, and your preferences all belong in the decision.[22]

The label includes concerns associated with late-pregnancy exposure to serotonin-related antidepressants, including newborn adaptation problems and persistent pulmonary hypertension. Much of that warning comes from the broader medication class. It should not be presented as a precise vilazodone-specific risk estimate. Tell the obstetric and newborn-care teams what you take.[1,22]

Use in the month before delivery may also increase bleeding after birth. This warning comes mainly from observational SSRI studies, so it does not give a precise risk estimate for vilazodone. Discuss delivery planning with the obstetric team.[1]

Breastfeeding data are also sparse. LactMed notes the lack of published experience and says an alternative may be preferred, especially for a newborn or premature infant. This calls for an individualized discussion about treatment and feeding, not an automatic instruction to stop breastfeeding or stop a medicine that has been helping.[23]

Two pediatric depression trials failed to demonstrate efficacy. In the later trial, the fluoxetine comparison group also did not separate significantly from placebo, which complicates interpretation. Even so, these studies do not establish vilazodone as an effective pediatric treatment, and it is not approved for children or teens.[24,25]

Older adults may have more interactions or greater vulnerability to dehydration, falls, or low sodium. Kidney or liver impairment does not automatically require a vilazodone dose adjustment within the ranges studied in the label, but medical complexity still matters. The prescriber should review the entire situation rather than treating a labeling statement as proof that monitoring is unnecessary.[1]

Follow-up and longer-term treatment

Follow-up should cover both benefit and burden: mood, anxiety, functioning, safety, sleep, sexual effects, adherence, and whether doses are taken with food. Ask when your first check-in will occur and how to reach the practice if symptoms worsen. NICE recommends a first review usually within two weeks, or after one week for people aged 18 to 25 or when suicide risk is a particular concern. This is general depression guidance, not a vilazodone-specific study finding.[21]

There is no universal blood-test panel required solely because someone takes vilazodone. Testing depends on symptoms, medical history, and other medicines. For example, a clinician may check sodium in someone at risk or investigate a medical problem that resembles depression. Routine blood levels are not part of the standard label-based dosing approach.[1,4]

Feeling better does not always mean treatment should end immediately. Depression guidelines often recommend continuing an effective antidepressant for at least six months after remission, with longer treatment considered for recurrent illness or ongoing risk. That is general depression guidance, not a fixed prescription for every patient.[21]

Vilazodone’s own maintenance evidence deserves a qualification. A randomized withdrawal trial enrolled responders after open treatment and compared continued vilazodone with placebo for 28 weeks. It did not show a significant difference in time to relapse. Relapse was uncommon in all groups, which limited what the trial could establish. It is neither proof of relapse prevention nor a reason to abruptly stop a medicine that is helping.[17]

For more on duration, read how long to stay on an antidepressant.

Stopping or switching Viibryd and withdrawal

Vilazodone is not a controlled substance, but that does not mean stopping it cannot cause symptoms. Addiction involves patterns such as compulsive use despite harm. Physical adaptation and withdrawal are different issues. Dizziness, nausea, sleep problems, anxiety, irritability, and electric-shock-like sensations can occur after a dose reduction or stopping.[1,2]

Withdrawal may start within days. Symptoms can be brief, but some people have more severe or longer-lasting difficulties. General antidepressant guidance recognizes that symptoms may last weeks and sometimes months. A gradual, adjustable plan is more useful than assuming every person can stop on the same schedule.[21]

The vilazodone label gives a short example taper. That is not proof that the same schedule will suit everyone after long-term treatment. A history of withdrawal, duration of use, available tablet strengths, and current symptoms may justify a slower plan. Ask how you will contact the prescriber and what to do if symptoms appear before beginning a reduction.[1,21]

Withdrawal and relapse can overlap. Timing, new physical sensations, and the pattern of mood symptoms may help a clinician assess what is happening, but no single clue makes the distinction certain. Do not invent an alternate-day schedule or a cross-taper with another medicine. Some switches need different precautions, and MAOI switches require a specific washout period.[1,21]

For a step-by-step look at tapering, see stopping an antidepressant: tapering and withdrawal.

Viibryd vs. Trintellix and other antidepressants

The table covers selected adult uses and practical differences. It is not a ranking and does not list every indication, risk, or interaction. Food instructions refer to the listed oral products.[1,27,28,29,30,31]

Viibryd and Trintellix are different medicines, not brand and generic versions of each other. A small 2024 open-label comparison favored vortioxetine on some outcomes. Because it was small, unblinded, and relied on completers for efficacy analysis, it cannot establish a reliable hierarchy for everyone. Several publications came from that same trial and should not be counted as separate replications.[31,34]

The best discussion starts with what matters to you: previous response, the main diagnosis, physical health, side effects you most want to avoid, meal routines, and cost. A medicine that looks appealing on a receptor diagram may still be a poor fit for daily life.

How family and friends can help

Ask what support the person wants. With permission, help organize questions, prepare a meal at dose time, or plan refills. Notice changes in sleep, activity, or behavior and describe them plainly. “You have slept much less for three nights” is more useful than a judgment about attitude.

Keep privacy and independence in view. Support is not surveillance, and ordinary disagreement is not a symptom by itself. Ask before attending visits or sharing information, except when urgent safety concerns require immediate help. A family member can also seek support for the strain of caring for someone with depression.

Medication does not replace connection, therapy, or help with practical burdens. Small shared activities can be easier than pressure to act cheerful. Progress may include returning a call, keeping an appointment, or taking part in a routine again. Let the person describe what feels different rather than deciding for them.[4]

More ideas are in supporting someone with depression.

Ten questions for the next appointment

1. Which diagnosis and symptoms are we treating with vilazodone?

2. Is any part of the plan off-label, and what supports that choice?

3. What would meaningful improvement look like for me?

4. When will we review benefit, side effects, and safety?

5. Which meal and dose time best fit my routine?

6. Do any of my medicines, supplements, or OTC products interact?

7. What should I do about sexual effects, stomach problems, or sleep changes?

8. What should I do if I miss a dose, vomit, or cannot obtain a refill?

9. Is generic vilazodone covered, and what is the likely pharmacy cost?

10. If this treatment does not fit, what is our plan for changing or stopping it safely?

Bring the questions that matter most and a short record of what you have noticed. The goal is a treatment plan you understand, can follow, and can revise with your clinician.

Frequently asked questions

What is Viibryd used for?

Its US approval is for major depressive disorder in adults. Other uses need their own evidence discussion and are off-label.[1]

Is Viibryd an SSRI?

It inhibits serotonin reuptake, as SSRIs do, and also partially activates 5-HT1A receptors. The extra action does not prove better results.[1]

Is vilazodone the generic version of Viibryd?

Yes. FDA-approved generic vilazodone has the same active medicine. Appearance, inactive ingredients, availability, and price can vary.[3,33]

Is Viibryd the same as Trintellix?

No. Viibryd is vilazodone; Trintellix is vortioxetine. Both affect serotonin, but they are distinct drugs with different receptor actions, food instructions, and interactions.[1,31]

Can Viibryd help anxiety?

It may help anxiety that accompanies depression. Trials also suggest modest short-term benefit in generalized anxiety disorder, but that is not an FDA-approved use.[8,9,10,11]

Why must I take Viibryd with food?

Food changes absorption. Taking vilazodone while fasting can lead to substantially lower blood exposure. The label does not specify one minimum calorie count for all patients.[1]

Should I take Viibryd in the morning or at night?

Ask which consistent meal and time fit your sleep and side-effect pattern. Keep the food requirement in the plan.[1,2]

How long will Viibryd take to work?

Allow for several weeks and scheduled reviews. General antidepressant guidance describes four to eight weeks, but response varies and severe worsening needs earlier attention.[4]

What if I forget a dose?

Take it when remembered unless the next dose is nearly due. Then skip it. Never double the dose; ask the pharmacist when the timing is unclear.[2]

What if I vomit after taking it?

Do not automatically redose. The label states no replacement dose is needed if vomiting occurs within seven hours. Seek advice for repeated vomiting or dehydration.[1]

Does Viibryd cause sexual side effects?

It can. Average questionnaire findings and individual adverse-event reports differ, so neither a low average effect nor receptor theory can promise protection.[19,20]

Will I gain weight on Viibryd?

Not everyone does. Short-term average changes were small, but longer-term weight gain occurred in some participants. “Weight neutral” should not be interpreted as “weight cannot change.”[7,18]

Can Viibryd affect sleep?

Yes. Insomnia and sleepiness are both reported. Discuss persistent changes rather than adding a sleep aid without checking interactions.[1,2]

Can I drink alcohol on Viibryd?

The Medication Guide advises avoiding alcohol. Unchanged absorption in an experiment does not establish that drinking is safe during treatment.[1]

Is Viibryd addictive?

It is not a controlled substance. However, physical adaptation and withdrawal can occur, so “not addictive” is not a reason to stop suddenly.[1,21]

Can I stop once I feel better?

Discuss the decision first. Continuing treatment after remission may reduce risk of another episode, while any eventual taper should fit your history and symptoms.[21]

Is Viibryd safe in pregnancy or breastfeeding?

Vilazodone-specific human evidence is limited. Make a plan with the psychiatric and obstetric teams, weighing the risks of illness and treatment. Do not stop abruptly because of a positive pregnancy test.[22,23]

Can children or teenagers take Viibryd?

It is not approved for pediatric use. Two depression trials did not demonstrate efficacy, so adult results should not be assumed to apply to children.[24,25]

Do I need routine blood tests?

There is no universal panel required just for vilazodone. Testing is based on medical history, symptoms, and interacting medicines.[1,4]

What if it helps but the side effects are hard to live with?

Tell the prescriber which effects matter and how they interfere with life. A meaningful benefit does not make those concerns unimportant. Discuss options before changing doses yourself.

Related reading on NP FADY

• Stopping an antidepressant: tapering and withdrawal
• How long to stay on an antidepressant
• Supporting someone with depression
• Drug interactions to know: antidepressants, alcohol, CBD, and more
• Serotonin and SSRIs: what it actually does
• Antidepressant side effects no one warned me about

Educational disclaimer

This article is for education. It does not diagnose any condition, choose a medication for anyone, or replace the judgment of the clinician who knows your history. Do not start, stop, or change any medication without your prescriber. If there is imminent danger, or you cannot keep yourself or someone else safe, call 911 or go to the nearest emergency department. In the United States, call or text 988, or chat at 988lifeline.org, for any mental-health crisis. For a suspected overdose or accidental ingestion, call Poison Help at 1-800-222-1222. Regulatory and numeric claims in this article were checked against current FDA labeling and primary studies on September 30, 2026. Labels, approvals, and availability change; confirm current status with your prescriber or pharmacist before acting on anything here.

References

1. AbbVie and FDA. VIIBRYD prescribing information and Medication Guide. FDA supplement 25 approved April 19, 2024; prescribing-information revision October 2023; Medication Guide revision April 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022567s025lbl.pdf. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022567. Accessed 2026-09-30.
2. MedlinePlus. Vilazodone drug information. https://medlineplus.gov/druginfo/meds/a611020.html. Accessed 2026-09-30.
3. FDA. Generic Drug Facts. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts. Accessed 2026-09-30.
4. National Institute of Mental Health. Depression. https://www.nimh.nih.gov/health/publications/depression. Accessed 2026-09-30.
5. Rickels K et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:326–333. DOI 10.4088/JCP.08m04637. https://pubmed.ncbi.nlm.nih.gov/19284933/. Accessed 2026-09-30.
6. Khan A et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011;72:441–447. DOI 10.4088/JCP.10m06596. https://pubmed.ncbi.nlm.nih.gov/21527122/. Accessed 2026-09-30.
7. Mathews M et al. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2015;30:67–74. DOI 10.1097/YIC.0000000000000057. https://pmc.ncbi.nlm.nih.gov/articles/PMC4314105/. Accessed 2026-09-30.
8. Thase ME et al. Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29:351–356. DOI 10.1097/YIC.0000000000000045. https://pubmed.ncbi.nlm.nih.gov/24978955/. Accessed 2026-09-30.
9. Gommoll C et al. A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder. Depress Anxiety. 2015;32:451–459. DOI 10.1002/da.22365. https://pmc.ncbi.nlm.nih.gov/articles/PMC4676920/. Accessed 2026-09-30.
10. Gommoll C et al. Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study. Int Clin Psychopharmacol. 2015;30:297–306. DOI 10.1097/YIC.0000000000000096. https://pmc.ncbi.nlm.nih.gov/articles/PMC4593467/. Accessed 2026-09-30.
11. Durgam S et al. Efficacy and safety of vilazodone in patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled, flexible-dose trial. J Clin Psychiatry. 2016;77:1687–1694. DOI 10.4088/JCP.15m09885. https://www.psychiatrist.com/jcp/vilazodone-in-generalized-anxiety-disorder/. Accessed 2026-09-30.
12. Careri JM et al. A 12-week double-blind, placebo-controlled, flexible-dose trial of vilazodone in generalized social anxiety disorder. Prim Care Companion CNS Disord. 2015;17(6). DOI 10.4088/PCC.15m01831. https://www.psychiatrist.com/pcc/week-double-blind-placebo-controlled-flexible-dose/. Accessed 2026-09-30.
13. Ramaswamy S et al. A double-blind, placebo-controlled randomized trial of vilazodone in the treatment of posttraumatic stress disorder and comorbid depression. Prim Care Companion CNS Disord. 2017;19(4):17m02138. DOI 10.4088/PCC.17m02138. https://pubmed.ncbi.nlm.nih.gov/28858440/. Accessed 2026-09-30.
14. ClinicalTrials.gov. NCT05948579. Department of Defense PTSD Adaptive Platform Trial, Intervention B, vilazodone. Last update posted May 20, 2026. https://clinicaltrials.gov/study/NCT05948579. Accessed 2026-09-30.
15. Schneier FR et al. A randomized controlled pilot trial of vilazodone for adult separation anxiety disorder. Depress Anxiety. 2017;34:1085–1095. DOI 10.1002/da.22693. https://pubmed.ncbi.nlm.nih.gov/29071764/. Accessed 2026-09-30.
16. McRae-Clark AL et al. Vilazodone for cannabis dependence: a randomized, controlled pilot trial. Am J Addict. 2016;25:69–75; online December 2015. DOI 10.1111/ajad.12324. https://pubmed.ncbi.nlm.nih.gov/26685701/. Accessed 2026-09-30.
17. Durgam S et al. Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2018;33:304–311. DOI 10.1097/YIC.0000000000000236. https://pmc.ncbi.nlm.nih.gov/articles/PMC6166708/. Accessed 2026-09-30.
18. Liebowitz M, Croft HA, Kajdasz DK, et al. The safety and tolerability profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Psychopharmacol Bull. 2011;44(3):15-33. PMID 27738360. https://pmc.ncbi.nlm.nih.gov/articles/PMC5044546/ Accessed 2026-09-30.
19. Clayton AH et al. The effect of vilazodone on sexual function during the treatment of major depressive disorder. J Sex Med. 2013;10:2465–2476. DOI 10.1111/jsm.12004. https://pubmed.ncbi.nlm.nih.gov/23216998/. Accessed 2026-09-30.
20. Clayton AH et al. Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study. Int Clin Psychopharmacol. 2017;32:27–35. DOI 10.1097/YIC.0000000000000145. https://pmc.ncbi.nlm.nih.gov/articles/PMC5131696/. Accessed 2026-09-30.
21. NICE. Depression in adults, treatment and management. NG222. Recommendations, especially 1.4.11–1.4.22. Published 2022, updated guidance checked during this review. https://www.nice.org.uk/guidance/ng222/chapter/Recommendations. Accessed 2026-09-30.
22. MotherToBaby. Vilazodone, Viibryd. Fact sheet, September 2023. https://mothertobaby.org/fact-sheets/vilazodone-viibryd/. Accessed 2026-09-30.
23. National Institute of Child Health and Human Development. Vilazodone. Drugs and Lactation Database, LactMed. Last revision April 18, 2022. https://www.ncbi.nlm.nih.gov/books/NBK501794/. Accessed 2026-09-30.
24. Durgam S et al. A phase 3, double-blind, randomized, placebo-controlled study of vilazodone in adolescents with major depressive disorder. Paediatr Drugs. 2018;20:353–363. DOI 10.1007/s40272-018-0290-4. https://pubmed.ncbi.nlm.nih.gov/29633166/. Accessed 2026-09-30.
25. Findling RL, McCusker E, Strawn JR. A randomized, double-blind, placebo-controlled trial of vilazodone in children and adolescents with major depressive disorder with twenty-six-week open-label follow-up. J Child Adolesc Psychopharmacol. 2020;30:355–365. DOI 10.1089/cap.2019.0176. https://pubmed.ncbi.nlm.nih.gov/32460523/. Accessed 2026-09-30.
26. Boinpally R et al. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects. Clin Ther. 2014;36:1638–1649. DOI 10.1016/j.clinthera.2014.08.003. https://pubmed.ncbi.nlm.nih.gov/25236915/. Accessed 2026-09-30.
27. AbbVie. Lexapro prescribing information. https://www.rxabbvie.com/pdf/lexapro_pi.pdf. Accessed 2026-09-30.
28. Viatris. Zoloft prescribing information, DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fda754f6-d0f3-4dce-a17a-927d64f912f7. Accessed 2026-09-30.
29. Eli Lilly. Cymbalta prescribing information. https://pi.lilly.com/us/cymbalta-pi.pdf. Accessed 2026-09-30.
30. Bausch Health and FDA. Wellbutrin XL prescribing information, November 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021515s049lbl.pdf. Accessed 2026-09-30.
31. Takeda. Trintellix prescribing information. Revision February 2025, DailyMed listing updated March 5, 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a5b68e2-14d0-419d-9ec6-1ca97145e838. Accessed 2026-09-30.
32. National Capital Poison Center. Poison Control. https://www.poison.org/. Accessed 2026-09-30.
33. DailyMed. Generic vilazodone hydrochloride tablets, label revised February 2025. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a70fd858-cbef-7336-d7ce-c78499031644. Accessed 2026-09-30.
34. Santi NS et al. A randomized controlled trial comparing efficacy and safety of antidepressant monotherapy. Cureus. 2024;16:e59074. DOI 10.7759/cureus.59074. https://pubmed.ncbi.nlm.nih.gov/38800340/. Same-cohort reports: PMID 39011217, 39328643, and 39539917; all cite CTRI/2022/07/043808. Accessed 2026-09-30.
35. Kalenderoglou IE et al. Structural basis of vilazodone dual binding mode to the serotonin transporter. Nat Commun. 2025;16:10119. DOI 10.1038/s41467-025-65202-3. https://pubmed.ncbi.nlm.nih.gov/41253806/. Accessed 2026-09-30.
36. ClinicalTrials.gov. NCT01828515. Vilazodone for corticosteroid-induced memory impairment. Completed, results posted. https://clinicaltrials.gov/study/NCT01828515. Accessed 2026-09-30.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, or chat at 988lifeline.org, available 24/7, free and confidential. En español: marque 988 y oprima 2, o envíe AYUDA al 988. Deaf or hard of hearing: 988 videophone (ASL) or TTY 711 then 988. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.